Tabula Rasa HealthCare (NASDAQ:TRHC) posted its quarterly earnings results on Monday, March 12th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.03), Bloomberg Earnings reports. The firm had revenue of $43.93 million for the quarter, compared to analysts’ expectations of $38.91 million. Tabula Rasa HealthCare had a negative return on equity of 1.96% and a net margin of 10.63%. The company’s revenue for the quarter was up 60.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 earnings per share.
Tabula Rasa HealthCare stock traded up $2.51 during mid-day trading on Thursday, reaching $38.94. The company had a trading volume of 508,257 shares, compared to its average volume of 361,033. Tabula Rasa HealthCare has a 1 year low of $11.59 and a 1 year high of $41.83. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 0.01. The stock has a market cap of $732.29, a PE ratio of -973.50, a price-to-earnings-growth ratio of 8.13 and a beta of 2.39.
Several research analysts recently issued reports on TRHC shares. BidaskClub cut shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. William Blair started coverage on shares of Tabula Rasa HealthCare in a report on Monday, December 11th. They set an “outperform” rating for the company. Oppenheimer started coverage on shares of Tabula Rasa HealthCare in a report on Monday, December 18th. They set an “outperform” rating and a $35.00 price target for the company. Zacks Investment Research cut shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, Citigroup started coverage on shares of Tabula Rasa HealthCare in a report on Thursday, January 4th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. Tabula Rasa HealthCare has an average rating of “Buy” and a consensus price target of $36.40.
A hedge fund recently raised its stake in Tabula Rasa HealthCare stock. State Street Corp grew its holdings in Tabula Rasa HealthCare Inc (NASDAQ:TRHC) by 38.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,673 shares of the company’s stock after purchasing an additional 19,506 shares during the quarter. State Street Corp owned approximately 0.40% of Tabula Rasa HealthCare worth $1,051,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 47.28% of the company’s stock.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.